the Flublok quadrivalent flu vaccine, the only recombinant protein-based flu jab approved by the FDA. David Loew, head of Sanofi Pasteur, the company’s vaccines division, said the acquisition ...

Sanofi said it has temporarily suspended ... All the trivalent Vaxigrip and the quadrivalent VaxigripTetra seasonal flu vaccines that were already distributed meet the necessary specifications ...

At Sanofi Pasteur, we believe in a world in which no one suffers or dies from a vaccine-preventable disease. As the world’s leading manufacturer of influenza vaccines, we know influenza is still ...

Sanofi Pasteur, the French firm’s vaccines arm, is one of several manufacturers including GlaxoSmithKline that make “quadrivalent” flu vaccines, covering against four major strains.

As well as Sanofi Pasteur MSD for providing funding ... countries to decide to recommend a trivalent or a quadrivalent influenza vaccine.

Sanofi has announced that its two combination vaccine candidates, designed to prevent both influenza and Covid-19 infections in people aged 50 years and above, have received fast track designation ...

The US Food and Drug Administration has granted Fast Track designation to two Sanofi combination vaccine candidates to prevent influenza and COVID-19 infections in individuals 50 years of age and ...

Roman Chicz, Global Head, External Research and Development, Sanofi ... include vaccine candidates against COVID-19, RSV, Streptococcus pneumoniae, acne and broadly protective influenza; pediatric ...

We assessed an inactivated quadrivalent influenza vaccine (QIV) containing both B lineages versus TIV in young children. Methods Children aged 18–47 months who had received 2 doses of TIV in a ...

Sanofi SNY announced that the FDA has granted a Fast Track designation to two combination vaccine candidates to prevent influenza and COVID-19 infections in people aged 50 years and above.

SK bioscience and Sanofi have announced plans for global Phase III studies, which will assess the safety and immunogenicity of their 21-valent pneumococcal conjugate vaccine candidate, GBP410 ...